Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status

Arch Dis Child. 2018 Dec;103(12):1150-1154. doi: 10.1136/archdischild-2017-313910. Epub 2018 Mar 7.

Abstract

Objectives: To evaluate pharmacokinetics of first-line antitubercular drugs, isoniazid (INH) and pyrazinamide (PZA), with revised WHO dosages and to assess its adequacy in relation to age and nutritional status.

Design: Observational study.

Setting: This study was conducted at Sarojini Naidu Medical College, Agra, and National Institute for Research in Tuberculosis, Chennai.

Patients: 40 subjects diagnosed with tuberculosis were registered in the study and started on daily first-line antitubercular regimen based on the revised WHO guidelines.

Interventions: Blood samples were collected at 0, 2, 4, 6 and 8 hours from these subjects after 15 days of treatment for drug estimations.

Main outcome measure: The measurement of drug concentrations (maximum peak concentration (Cmax) and area under the time -concentration curve (AUC0-8 hours)) for INH and PZA. Appropriate statistical methods were used to evaluate the impact of age and nutritional status on pharmacokinetic variables.

Results: For INH, the difference in drug exposures in children <3 years (Cmax 3.18 µg/mL and AUC0-8 hours15.76 µg/mL hour) and children >3 years (Cmax3.05 µg/mL and AUC0-8 hours 14.37 µg/mL hour) was not significant (P=0.94, P=0.81, respectively). The drug levels in children with low body mass index (BMI) (Cmax3.08 µg/mL; AUC0-8 hours14.81 µg/mL hour) were also comparable with their normal counterparts (Cmax3.09 µg/mL, P=0.99; AUC0-8 hours 14.69 µg/mL hour, P=0.82). PZA drug exposures obtained in children less than 3 years (Cmax29.22 µg/mL, AUC0-8 hours 155.45 µg/mL hour) were significantly lower compared with drug levels in children above 3 years (Cmax 37.12 µg/mL, P=0.03; AUC 202.63 µg/mL hour, P value=0.01). Children with low BMI had significantly lower drug concentrations (Cmax 31.90 µg/mL, AUC0-8 hours167.64 µg/mL hour) when compared with normal counterparts (Cmax 37.60 µg/mL, P=0.02; AUC0-8 hours 208.77 µg/mL hour, P=0.01).

Conclusions: The revised WHO drug dosages were found to be adequate for INH with respect to age and nutritional status, whereas PZA showed significantly lower drug levels in children <3 years and in malnourished children.

Keywords: antituberculosis drugs; children; malnutrition; pharmacokinetics; tuberculosis.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Age Factors
  • Antitubercular Agents / blood
  • Antitubercular Agents / pharmacokinetics*
  • Antitubercular Agents / therapeutic use
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Isoniazid / blood
  • Isoniazid / pharmacokinetics*
  • Isoniazid / therapeutic use
  • Male
  • Malnutrition / complications
  • Multivariate Analysis
  • Nutritional Status
  • Practice Guidelines as Topic
  • Pyrazinamide / blood
  • Pyrazinamide / pharmacokinetics*
  • Pyrazinamide / therapeutic use
  • Treatment Outcome
  • Tuberculosis / blood
  • Tuberculosis / complications
  • Tuberculosis / drug therapy*

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Isoniazid